H3. Proxima Nova Bold 16px

H4. Proxima Nova Light 24 px #000000

H5. Proxima Nova Regular 12px #404040

p. Proxima Nova Regular 14px. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam condimentum libero vitae dui vulputate, a gravida arcu pulvinar. Cras pellentesque molestie euismod. Fusce rutrum pulvinar ante id aliquam. Donec fringilla augue ut quam tempor, at consectetur nibh feugiat.

This is a link Proxima Nova Regular 14px

  • Proxima Nova Regular 14px. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
  • Proxima Nova Regular 14px. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
  • Proxima Nova Regular 14px. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
  1. Proxima Nova Regular 14px. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
  2. Proxima Nova Regular 14px. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
  3. Proxima Nova Regular 14px. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Open Positions • US

Frequently Asked Questions About Clinical Trials

Clinical trials are medical research studies that test new ways to prevent, screen, diagnose, or treat a disease by allowing the evaluation of potential new medical and treatment options. These studies are the result of long and deliberate preclinical drug development that often spans years even before the new therapy is tested in a patient. In the United States, all new drugs must proceed through an orderly clinical trial evaluation process – Phase 1, 2 and 3 – to ensure that they have an acceptable level of safety and demonstrate a clinical benefit in helping patients with the disease they target before they can become commercially available to other patients.

Clinical trials are medical research studies that test new ways to prevent, screen, diagnose, or treat a disease by allowing the evaluation of potential new medical and treatment options. These studies are the result of long and deliberate preclinical drug development that often spans years even before the new therapy is tested in a patient. In the United States, all new drugs must proceed through an orderly clinical trial evaluation process – Phase 1, 2 and 3 – to ensure that they have an acceptable level of safety and demonstrate a clinical benefit in helping patients with the disease they target before they can become commercially available to other patients.

Clinical trials are medical research studies that test new ways to prevent, screen, diagnose, or treat a disease by allowing the evaluation of potential new medical and treatment options. These studies are the result of long and deliberate preclinical drug development that often spans years even before the new therapy is tested in a patient. In the United States, all new drugs must proceed through an orderly clinical trial evaluation process – Phase 1, 2 and 3 – to ensure that they have an acceptable level of safety and demonstrate a clinical benefit in helping patients with the disease they target before they can become commercially available to other patients.

Clinical trials are medical research studies that test new ways to prevent, screen, diagnose, or treat a disease by allowing the evaluation of potential new medical and treatment options. These studies are the result of long and deliberate preclinical drug development that often spans years even before the new therapy is tested in a patient. In the United States, all new drugs must proceed through an orderly clinical trial evaluation process – Phase 1, 2 and 3 – to ensure that they have an acceptable level of safety and demonstrate a clinical benefit in helping patients with the disease they target before they can become commercially available to other patients.

Overview

Tcell Receptor

Overview

Antigen

Management Team

James Noble

James Noble MA FCA

Chief Executive Officer

James has over two decades of experience in biotechnology, having served on public and private boards of companies in the UK, the USA and Germany. At the executive level, he served as CFO of British Biotech plc from 1990 to 1997, where he was responsible for raising over £300 million in equity capital from the UK, USA, Japan and continental Europe and for the simultaneous listing in London and on NASDAQ. James was the CEO of Avidex (the predecessor company of Adaptimmune) from 2000 and 2006 when the company was sold to MediGene AG, where James joined the supervisory board. James was responsible for the spin-outs of both Immunocore and Adaptimmune from MediGene in 2008 and served as CEO of both. In March 2014, James relinquished his position as CEO of Immunocore in order to focus exclusively as CEO of Adaptimmune, although he remains a non-executive director of Immunocore.

At the non-executive level, James has served on a number of boards including: Oxford Glycosciences plc, Curagen Inc, PowderJect Pharmaceuticals plc and was the founding chairman of Biovex. He is currently Deputy Chairman at GW Pharmaceuticals plc, a NASDAQ and AIM-listed biotech company.

Prior to his involvement in the biotech industry, James graduated from Oxford in 1980 and qualified as a chartered accountant with Price Waterhouse in 1983. He then spent seven years at Kleinwort Benson Limited, reaching Director in 1990.

Company Overview

With a research base in Oxford, UK and a clinical base in Philadelphia, US, Adaptimmune is focused on the use of T cell therapy to treat cancer. It aims to utilise the body’s own machinery – the T cell – to target and destroy cancerous by using engineered, increased affinity T cell receptors (TCRs) as a means of strengthening natural patient T cell responses.